

MEDICUS

JOURNAL OF THE FACULTY OF MEDICAL TECHNICAL SCIENCES

No 2/2018

ISSN 2663-7758

Editor-in-Chief:

Prof. Dr. Isuf Kalo

Editor

Alda Bardhyli, European University of Tirana

Members of the Editorial Board:

Dr. Marsida Duli - European University of Tirana

Prof. Asoc. Dr. Voltisa Lama - European University of Tirana

Prof. Asoc. Dr. Aleksandër Dhima - European University of Tirana

Dr. Qamil Dika - University of Sports Tirana

Prof. Dr. Nestor Thereska - European University of Tirana

Prof. Dr. Fedhon Meksi - European University of Tirana

Prof. Dr. Arben Ivanaj - University Hospital Center "Mother Teresa"

Prof. Dr. Bajram Hysa - Medical University of Tirana

Prof. Dr. Edi Kakarriqi - Public Health Institute

Prof. Dr. Edvin Prifti - Medical University of Tirana

Dr. Arben Gjoni - University Hospital of Trauma

Graphic design

Besnik Frashni



UETPRESS

Abstracts of XIII Congress of Albanian Association of Hematology

Published under the series "ACADEMIC JOURNALS".

© 2018 UET Press. All rights reserved.

No part of this publication may be reproduced, stored in or introduced into a retrieval system, or transmitted, in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the written permission of the copyright owner.

European University of Tirana
University Press "UET Press"
Address: Bulevardi "Gjergj Fishta", Nd.70, H.1, Postal Code 1023, Tirana, Albania.
polis@uet.edu.al
www.uet.edu.al/polis

Polis journal has been catalogued at the National Library of Albania and the Library of the European University of Tirana, Albania.



Published by:
EUROPEAN UNIVERSITY OF TIRANA / ALBANIA
Bulevardi "Gjergj Fishta", Nd. 70, H1, Tirana, Albania
www.uet.edu.al / polis@uet.edu.al



Albanian Association of Hematology, AAH
Congress XIII on 5, 6 November 2018, Plaza Hotel, Tirana, Albania.

Tiranë, 2018.

content

<i>CAR- T cell the new treatment in lymphoid neoplasia</i>	7
A. Ivanaj, A. Cili, A. Perolla, P. Pulluqi, E. Calliku T. Caja, E. Pepa, R. Roxhani, T. Dedej	
<i>Chronic myeloid leukemia 2018 update on diagnosis, therapy and monitoring</i>	8
A. Cili, A. Perolla, E. Calliku, P. Pulluqi, T. Caja, A. Ivanaj	
<i>A very rare case of transformation of a patient with Multiple Myeloma to Non Hodgkin malignant lymphoma</i>	10
A. Cili, L. Lacej, E. Pepa, R. Tozharaku, A. Ivanaj	
<i>Te dhëna epidemiologjike të mielomës multiple në Shqipëri</i>	12
A. Çyrbja, T. Caja, A. Cili, A. Perolla, P. Pulluqi, E. Calliku, A. Ivanaj	
<i>Treatment of Mantle Cell Lymphoma</i>	15
A. Hate, A. Cili, A. Perolla, T. Caja, P. Pulluqi, E. Calliku, A. Pushi, A. Ivanaj	
<i>Next-generation sequencing - a new era in hematological malignancies</i>	16
A. Perolla, P.Pulluqi, A.Ivanaj, E.Calliku, A.Cili, T.Caja	
<i>“Next-generation sequencing - a new era in hematological malignancies”</i>	18
A. Perolla, P.Pulluqi, A.Ivanaj, E.Calliku, A.Cili and T.Caja	
<i>Leukemia Akute Limfoblastike, te dhena epidemiologjike per periudhen 2008-2018 ne Shqiperi</i>	20
A. Papa, A. Cili, P. Pulluqi, A. Perolla, T. Caja, E. Calliku dhe A. Ivanaj	
<i>Acute Lymphoid leukemia in Albania, retrospective study</i>	23
Genta Smaja, A. Cili, T. Caja, P. Polluqi, A. Perolla, E. Calliku, A. Ivanaj	
<i>The Registers of chronic diseases in Albania</i>	25
Albana A. Fico, Alban Ylli, Elizana Petrela, Bajram Dedja	
<i>Treatment of acute myeloid leukemia based on citogenetics and molecular biology</i>	27
Polikron Pulluqi, Tatjana Caja, Adela Perolla, Alma Cili, Elsuarta Calliku, Marsela Shani, Xheni Ngjela, Anxhela Papa, Adela Buzo, Arben Ivanaj	

<i>Anemic syndrome in patients with Inflammatory Bowel Disease</i>	30
Skerdi Prifti, Marsela Sina, Adea Kocollari	
<i>“The hematologic complications in patients treated with antithyroid drugs”</i>	32
Prof. Agron Ylli, Th. Fureraj, V.Hoxha, G. Husi, M.Kermaj, R.Sanxhaku, E. Hoxha	
<i>Cellular cardiomyoplasty into infarcted swine’s hearts by retrograde infusion through the venous coronary sinus: An experimental study</i>	33
Prof. Edvin Prifti	
<i>“Current treatment for ITP”</i>	35
Elsuarta Calliku MD	
<i>Epidemiologjia e Leukemise Limfoide chronike ne vitet 2013-2017</i>	36
M.Shani, P.Pulluqi, T.Caja, A.Cili, E.Calliku, A.Perolla, Xh.Ngjela, A. Ivanaj	
<i>New era of target therapies and immunotherapies in solid tumours</i>	38
Erion DOBI M.D. Ph.D	
<i>Chronic Lymphocytic Leukemia: From Genes to Treatment</i>	41
Gianluca Gaidano	
<i>Rezultatet e mjekimit me DHAP- R ne linje te dyte ne te semuret me DLBCL</i> .	45
Eralda Pepa, A. Cili, R. Roxhani, T. Caja, A. Perolla, P. Pulluqi, E. Calliku, A. Ivanaj	
<i>Current treatment for Immune Thrombocytopenia</i>	47
Elsuarta Calliku (Jusufaj) MD, Marsela Shani, Adela Perolla MD, Prof. Polikron Pulluqi, Alma Cili MD, Ass.Prof. Tatjana Caja, Prof. Arben Ivanaj	
<i>Limfoma Hodgkin ne Shqiperi. Epidemiologjia (vitet 2008-2018) dhe trajtimi me skemen ABVD te kimioterapise</i>	49
Resmije Tozharaku, A. Cili, T. Caja, P. Pulluqi, A. Perolla, E. Carlliku, E. Pepa, A. Ivanaj	
<i>Surgery role in the treatment of abdominal NHML</i>	53
Prof. Arvin Dibra	
<i>Ndryshimet midis Mielomes Multiple sekretore dhe jo sekretore ne Kosove nga viti 2017 deri 2018</i>	54
A.Ukimeraj, V.Cavolli, E.Ismani, Sh. Sadiku	
<i>Leukemia akute mieloblastike. Te dhena epidemiologjike</i>	56
Xh. Ngjela, A. Cili, A. Perolla, P. Pulluqi, T. Caja, E. Calliku A. Ivanaj	

CAR- T cell the new treatment in lymphoid neoplasia

**A. Ivanaj, A. Cili, A. Perolla, P. Pulluqi, E. Calliku
T. Caja, E. Pepa, R. Roxhani, T. Dedej**

CAR T-cell therapy. A type of treatment in which a patient’s T cells (a type of immune cell) are changed in the laboratory so they will bind to cancer cells and kill them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which removes the white blood cells, including the T cells, and sends the rest of the blood back to the patient. Then, the gene for a special receptor called a chimeric antigen receptor (CAR) is inserted into the T cells in the laboratory. Millions of the CAR T cells are grown in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and kill them. In multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events. In the patients with ALL CAR T-cell therapy demonstrated very good response with a safety adviser site effects. CAR T-cell therapy is a safety and very promising treatment in lymphoid neoplasia.